Incyte (INCY) Q3 2026 earnings review
Incyte's newer drugs beat expectations, but lower prices slow Jakafi
Incyte's newer medicines are growing fast enough to lift the full-year plan, even as lower prices hold back its flagship drug Jakafi. Product sales rose 14% to $1.32 billion, led by a 37% jump across Opzelura skin cream and newer cancer drugs, while a $1.23 billion buyout charge pushed the biotechnology company into a net loss. Chief executive Bill Meury raised the full-year sales outlook, though by our math the plan points to product sales growth slowing to 10% in the fourth quarter.
| Total net product sales | $1.32B +14% from a year ago |
|---|---|
| Newer drugs outside Jakafi | $490M +37% from a year ago (37% of product sales) |
| GAAP net loss | -$785M includes $1.23B Vega buyout charge |
| Full-year product sales outlook | Raised $60M middle of the range: 21% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because the higher outlook comes from real prescription demand rather than an accounting credit. Last quarter's raise rested on a one-time Medicaid settlement, whereas this quarter's $60 million boost reflects patient growth in Opzelura, Niktimvo and Zynyz that cleared the top of the prior plan. One caution: lower net prices wiped out two-thirds of Jakafi's 12% volume growth, and Incyte stopped enrollment in a Phase 3 ovarian cancer trial.
The question now is whether Jakafi price erosion and clinical trial setbacks will undo the gains from the newer drug launches before 2028 patent expiries. Optimists see non-Jakafi sales already at 37% of the total and four late-stage medicines advancing toward 2027 approvals, while sceptics point to Jakafi slowing toward 2% implied growth in the fourth quarter and another halted trial. Fourth-quarter Phase 3 readouts for Opzelura and povorcitinib, alongside year-end Jakafi XR conversion numbers, will settle it.
🐂 Bull Case
Newer Drugs Forced a Clean Outlook Raise
Incyte, a biotechnology company that makes treatments for blood cancers and skin diseases, relies on Jakafi for most of its revenue. Chief executive Bill Meury wants newer medicines to carry growth before Jakafi loses patent protection in 2028, "creating a durable core business beyond Jakafi". This quarter, sales outside Jakafi rose 36.6% from a year ago to $490 million, reaching 37.2% of total product sales by our math.
- Hematology and oncology portfolio: $235 million, up 37.6% from a year ago
- Niktimvo, a treatment for transplant complications: $67.4 million, up 47.0%
- Zynyz, a skin and anal cancer medicine: $58.3 million, up 157.2%
- Monjuvi and Minjuvi, for lymphoma: $54.6 million, up 30.1%
Last quarter'soutlook raise rested on a $246 million accounting credit from a Medicaid settlement. This quarter had no one-time credit, yet the drugmaker lifted its full-year product sales plan by $60 million at the middle of the range because patient demand beat its prior assumptions.
What to watch: fourth-quarter sales for the hematology and oncology group. By our math, the new full-year plan leaves $240 million for the fourth quarter, or 27.9% growth, so another result above $245 million would show the newer cancer launches are still outrunning management's caution.
Opzelura Volume and Better Pricing Drove 36% Growth
Opzelura, Incyte's prescription cream for eczema and the skin-loss condition vitiligo, is its second-largest product. Sales rose 35.6% from a year ago to $254.9 million, and the company raised its full-year Opzelura outlook by $35 million at the middle of the range to between $1.10 billion and $1.12 billion.
Growth came from both more patients in eczema and vitiligo and "improvements in net pricing resulting from the Opzelura line extension settlement in the second quarter". That agreement with federal regulators lowered Incyte's Medicaid rebate bill, so the firm now keeps a larger share of every prescription dollar. European regulators also approved Opzelura for adults with moderate eczema in July.
What to watch: Phase 3 trial results (TRuE-HS1 and TRuE-HS2) for Opzelura in hidradenitis suppurativa, a painful inflammatory skin disease, due in the fourth quarter. A positive readout would open a third major skin condition for the cream.
Four Late-Stage Drugs Advance Toward 2027 Launches
Incyte needs several clinical trials to succeed to replace Jakafi revenue at the end of the decade. Meury said the company is advancing experimental medicines that "give us multiple paths to growth beyond 2029". This quarter delivered regulatory and clinical progress across four separate disease programs.
- INCA033989 (a targeted antibody for blood cancers): Phase 3 trial in myelofibrosis starts by year-end after FDA talks
- Povorcitinib (an oral pill for inflammatory skin diseases): European panel recommended approval in hidradenitis suppurativa in September
- Monjuvi (lymphoma antibody): US decision and potential launch in newly diagnosed patients expected in first-quarter 2027
- INCB161734 (a pill targeting KRAS G12D mutations): Phase 3 colorectal cancer trial starts in first-half 2027
What to watch: two Phase 3 data readouts (STOP-PN1 and STOP-PN2) for povorcitinib in prurigo nodularis, an itchy skin condition, expected in the fourth quarter. Positive results would add a second major use for the pill just as its first US launch begins in early 2027.
🐻 Bear Case
Lower Prices Ate Up Two-Thirds of Jakafi's Demand Growth
Jakafi, an oral drug for bone-marrow disorders and transplant complications, still brings in 62.8% of Incyte's product sales by our math. Meury said overall product sales growth was strong, and Incyte reported that paid patient demand for Jakafi rose 12% from a year ago across all approved uses.
Yet actual Jakafi revenue grew only 4.5% to $826.5 million. By our math, lower net prices and rebates wiped out 7.5 percentage points of that 12% volume gain. Incyte also left its full-year Jakafi outlook unchanged at $3.22 billion to $3.27 billion even though newer drugs beat expectations. By our math, that unchanged plan implies Jakafi growth slows to 1.9% in the fourth quarter.
What to watch: fourth-quarter Jakafi revenue and the exact dollar breakdown of price discounts in the quarterly filing. If price concessions keep taking most of the volume gains, Jakafi will generate less cash than planned before its patents expire in 2028.
Incyte Stopped Enrollment in Another Late-Stage Cancer Trial
Incyte's long-term plan relies on replacing Jakafi with new pipeline medicines, but clinical trial attrition continues to thin the list. Over the past year the drugmaker halted five programs or indications, including its lead JAK2 blood-cancer pill last quarter.
This quarter brought another stop for INCB123667, an experimental pill that blocks the CDK2 protein in tumors. The company stated that "As part of a strategic shift in focus toward the first-line maintenance ovarian cancer setting, enrollment in the Phase 3 study (MAESTRA-2) evaluating INCB123667 in patients with platinum-resistant ovarian cancer (PROC) was discontinued". Stopping a Phase 3 trial mid-stream delays the drug's path to market while Incyte starts a different trial (MAESTRA-3) late this year.
What to watch: Phase 1 data for INCA033989 in newly diagnosed myelofibrosis patients, due in the fourth quarter. Because INCA033989 is the centerpiece of the blood-cancer pipeline, any weak efficacy signal there would hurt the post-2028 replacement thesis.
The $1.23 Billion Vega Purchase Pushed Incyte Into a Loss
Incyte has built a $3.9 billion cash pile to buy external drugs, calling deals a core strength while critics point to rising share counts and zero buybacks. In July, the biopharma group closed its $1.25 billion buyout of Vega Therapeutics to get latarcibart, an antibody for the bleeding disorder von Willebrand disease.
Accounting rules required Incyte to book $1.23 billion of the purchase price inside research and development expenses this quarter. That lifted research spending by 78.0 percentage points of revenue to $1.79 billion and pushed the company to a $784.8 million net loss. Even excluding Vega, research costs rose 10.9%. Meanwhile, basic shares rose 3.9% from a year ago and Phase 3 data for latarcibart will not arrive until early 2029.
What to watch: fourth-quarter operating expense guidance for 2027 when full-year results arrive. Investors will see whether running Phase 3 trials for latarcibart and three other major assets keeps margins compressed next year.
Risks this quarter didn't answer
Four standing concerns from prior quarters received no new numbers in the third-quarter earnings release because the details live in the quarterly call or the 10-Q filing.
- Jakafi XR conversion: sales and insurance coverage for the new once-daily pill were folded into total Jakafi revenue without a separate figure; management promised a 3% to 5% demand share by year-end.
- Research spending by drug: research costs are still reported as a single line, leaving the cost of the four main pipeline programs undisclosed.
- Customer concentration: whether the top six wholesalers still hold over 63% of receivables awaits the 10-Q filing.
- Launch execution load: the first real test of the new commercial leadership team arrives in first-quarter 2027 with two planned US launches.
👓 Other Themes
Medicaid Pricing Deal Trades State Discounts for Mandate Relief
In August, Incyte signed a pricing agreement with the U.S. Centers for Medicare & Medicaid Services. The drugmaker will let state Medicaid programs buy Jakafi and Jakafi XR "at prices aligned with those in a defined group of other advanced, industrialized nations". In exchange, the company expects exemption from "certain future CMS pricing mandates, including the proposed GUARD and GLOBE models", trading lower state Medicaid prices for protection against broader federal price caps.
💲 Other KPIs
Money owed by customers rose 38.1% from a year ago and 20.8% since December, outpacing the 14.0% growth in third-quarter revenue by our math. Receivables have climbed for three straight quarters — from $1,051 million in the first quarter to $1,125 million in the second — tying up working capital as new drugs scale.
Future tax credits on the balance sheet shrank by $55 million this quarter and are down $234 million, or 45.3%, since December by our math. The asset has fallen every quarter this year — from $515 million at year-end to $453 million in Q1 and $337 million in Q2 — reducing book equity.
Marketing and overhead costs rose 10.7% from a year ago, or 9.9% excluding stock compensation, after growing 6.3% in the second quarter and 0.7% in the first. Incyte said the step-up funded commercial preparations ahead of upcoming product launches, though the line still fell by 0.7 percentage points of total revenue.
🔮 Guidance
Raised. The middle of the product sales range moved up $60 million to $5,255 million, or 20.7% growth for the year by our math. That leaves about $1,346 million for the fourth quarter, implying 10.1% growth vs 14.5% this quarter. It is the second raise this year (+$340M in Q2 from the Medicaid settlement, +$60M in Q3 from operations).
Unchanged. The plan still calls for about 4.9% growth at the middle of the range, including sales of the new once-daily Jakafi XR pill. By our math, that leaves $844 million for the fourth quarter, or 1.9% growth from a year ago against 4.5% this quarter, as lower net prices offset prescription volume gains.
Raised. Management lifted the middle of the outlook by $35 million to $1,110 million, or 63.6% reported growth including the second-quarter $246 million Medicaid credit. By our math, that leaves $262 million for the fourth quarter, or 26.6% growth from a year ago compared with 35.6% this quarter. Second raise this year (+$305M in Q2, +$35M in Q3).
Raised. The biopharma company boosted the middle of the range by $25 million to $900 million, or 54.3% full-year growth by our math. That leaves about $240 million for the fourth quarter, implying 27.9% growth from a year ago vs 37.6% this quarter as Niktimvo and Zynyz lap their first big launch quarters. Second raise this year (+$35M, +$25M).
Unchanged. The spending plan stays at $4,955 million at the middle of the range, up 44.6% for the year because it includes the $1.23 billion Vega buyout charge. By our math, that leaves $1,086 million for the fourth quarter, or 8.5% growth from a year ago, as pre-launch marketing and Phase 3 trial costs continue.
Unchanged. Operating costs excluding stock compensation remain at a $4,660 million middle, up 46.6% for the year including the Vega charge. By our math, the outlook leaves $992 million for the fourth quarter, up 5.5% from a year ago.
❓ Key Questions
How much did Jakafi XR sell in the third quarter?
Incyte folded once-daily Jakafi XR sales into total Jakafi revenue without giving a number. Management previously targeted $40 million to $50 million in full-year XR sales and a 3% to 5% demand share by December to protect revenue before 2028 generic entry.
How much will the new Medicaid deal cut Jakafi prices?
Incyte agreed in August to align state Medicaid prices for Jakafi with prices in other developed nations in exchange for exemption from future federal pricing models. Management has not disclosed what share of Jakafi volume goes to state Medicaid or the dollar impact for 2027.
Why did Incyte stop the Phase 3 ovarian cancer trial?
The company halted enrollment in the MAESTRA-2 Phase 3 study of INCB123667 for platinum-resistant ovarian cancer to focus on earlier-stage maintenance therapy. Investors need to know whether Phase 1 efficacy or safety data drove the decision to abandon the faster path to market.
What drove the 7.5-point price drag on Jakafi?
Jakafi paid demand grew 12% from a year ago, but net sales rose only 4.5% by our math. Investors need to know how much of that gap came from Medicare Part D redesign, commercial rebates, or introductory discounts on Jakafi XR.